Feldman S
UMC Children's Hospital, Jackson, Mississippi 39216-4505.
J Med Virol. 1993;Suppl 1:85-9. doi: 10.1002/jmv.1890410516.
Acyclovir has been approved in the United States and elsewhere as antiviral therapy for otherwise healthy children and adolescents with varicella. This development arose from multicentre placebo-controlled trials of acyclovir in normal patients, 2-18 years of age, which showed that the drug accelerated cutaneous healing, and reduced fever and related constitutional symptoms without harmful side effects. Acyclovir did not, however, decrease transmission of chickenpox within the household, nor was there any demonstrable effect of antiviral therapy on varicella complications. In this article, the background and rationale for the multicentre studies of acyclovir in normal paediatric patients with chickenpox is reviewed. The evidence for and against its routine administration within 24 hours of the eruption of skin rash is also discussed.
阿昔洛韦在美国及其他地区已被批准用于治疗原本健康的水痘患儿和青少年。这一进展源于在2至18岁正常患者中进行的关于阿昔洛韦的多中心安慰剂对照试验，试验表明该药物可加速皮肤愈合，减轻发热及相关全身症状，且无有害副作用。然而，阿昔洛韦并未减少家庭内水痘的传播，抗病毒治疗对水痘并发症也没有任何明显效果。本文回顾了在正常水痘儿科患者中进行阿昔洛韦多中心研究的背景和基本原理。还讨论了支持和反对在皮疹出现后24小时内常规使用阿昔洛韦的证据。
